Grant: Undergraduate Student Research Awards (USRA)
University of Alberta
$6,000.00
Waking up Hepatitis B virus (HBV)'s chronic form to maximize attack by promoter-targeting therapies
FY 2023-24
Summary
INTRO: Hepatitis B virus (HBV) remains chronic due to the persistence of its chronic form, the covalently closed circular DNA (cccDNA), which remains hidden in the nucleus, wrapped around histones and untargeted by current therapies. Thus, in the strategy toward HBV cure, targeting the cccDNA will be essential. We have recently discovered a 3D target within a key promoter of HBV. While we appear to have some activity with potential binders to this region, we want to explore the idea of maximizing our effects with combination therapy. That is, given our cccDNA target may be partly transcriptionally-silent from its histone-wrapped, epigenetically-controlled state, we want to see if we can "wake-up" this dormant form to expose more of the promoter-region target to which our binders can attach. One of the known transcriptional activators is a protein produced by HBV, HBx or X-protein. HYPOTHESIS: The overexpression of HBx and/or use of other epigenetic modifications will maximize the active cccDNA hidden in the cell, readying it for targeting by drugs. METHODS: Using the HepG2-NTCP cell line, a plasmid containing the HBx gene will be transfected to overexpress the protein, just prior to or just after infecting with HBV per lab protocols. Markers of HBV transcriptional output, including pre-genomic RNA, will be measured. Next, known epigenetic modulators, such as histone deacetylase inhibitors will be tried. All key experiments will be confirmed in primary human hepatocytes (PHHs) to ensure the findings are transferrable - particularly, among both male- and female-karyotyped PHHs. SIGNIFICANCE: This work will examine an important area of exploration in our lab which is seeking approaches to maximize application of our promoter-based cccDNA-targeting therapies.
Department
Program
Undergraduate Student Research Awards (USRA)
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486942
Name
Kasinyabo Emmanuelle
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Waking up Hepatitis B virus (HBV)'s chronic form to maximize attack by promoter-targeting therapies
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Alberta
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Cell; Chronic; Dna; Drugs; Epigenetic; Hepatitis B; Hepatocytes; Protein; Therapies
Abstract
INTRO: Hepatitis B virus (HBV) remains chronic due to the persistence of its chronic form, the covalently closed circular DNA (cccDNA), which remains hidden in the nucleus, wrapped around histones and untargeted by current therapies. Thus, in the strategy toward HBV cure, targeting the cccDNA will be essential. We have recently discovered a 3D target within a key promoter of HBV. While we appear to have some activity with potential binders to this region, we want to explore the idea of maximizing our effects with combination therapy. That is, given our cccDNA target may be partly transcriptionally-silent from its histone-wrapped, epigenetically-controlled state, we want to see if we can "wake-up" this dormant form to expose more of the promoter-region target to which our binders can attach. One of the known transcriptional activators is a protein produced by HBV, HBx or X-protein. HYPOTHESIS: The overexpression of HBx and/or use of other epigenetic modifications will maximize the active cccDNA hidden in the cell, readying it for targeting by drugs. METHODS: Using the HepG2-NTCP cell line, a plasmid containing the HBx gene will be transfected to overexpress the protein, just prior to or just after infecting with HBV per lab protocols. Markers of HBV transcriptional output, including pre-genomic RNA, will be measured. Next, known epigenetic modulators, such as histone deacetylase inhibitors will be tried. All key experiments will be confirmed in primary human hepatocytes (PHHs) to ensure the findings are transferrable - particularly, among both male- and female-karyotyped PHHs. SIGNIFICANCE: This work will examine an important area of exploration in our lab which is seeking approaches to maximize application of our promoter-based cccDNA-targeting therapies.
Competitiondate
202305
Approvedterm2
0 yr 4 mths
Pinamesdelim
Kasinyabo, Emmanuelle
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~